Greenwich LifeSciences (GLSI) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, gaining 32.3% versus a loss of 33.5%. Over five years, GLSI leads with a -60.1% price change compared with -80.1% for PRQR. Greenwich LifeSciences is the larger company by market cap ($236.3 million vs $225.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | PRQR |
|---|---|---|
| Share price | $16.10 | $1.60 |
| Market cap | $236.32M | $225.08M |
| 1-day change | +6.34% | +1.59% |
| YTD return | -27.94% | -22.28% |
| 1-year return | +32.28% | -33.47% |
| 5-year return | -60.12% | -80.08% |
| EPS (TTM) | $-1.53 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $3.10 |
| 52-week low | $7.78 | $1.33 |
| Distance from 52-week high | -52.79% | -48.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +254.04% | +387.77% |
| Average volume | 138.91K | 796.41K |
| Shares outstanding | 14.68M | 141.12M |
| Employees | — | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed PRQR by 65.8 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
GLSI vs PRQR FAQ
Which is bigger, Greenwich LifeSciences or ProQR Therapeutics N.V.?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $236.32M compared with $225.08M for ProQR Therapeutics N.V. (PRQR).
Which stock has performed better over the past year, GLSI or PRQR?
GLSI returned +32.28% over the past 12 months, compared with -33.47% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.